Lyo-Ready Direct RNA NASBA Urine
RT-qPCR became the standard for RNA detection because of widely available reagents and standardized workflows. Now you can unlock the advantages of isothermal RNA amplification without the complexity of developing Nucleic Acid Sequence-Based Amplification (NASBA) formulations in-house. Lyo-Ready Direct RNA NASBA Urine is a glycerol-free, lyophilization-ready NASBA mix designed for sensitive one-step RNA amplification directly from urine samples at 41 °C, eliminating the need for thermal cycling or thermal denaturation. Lyo-Ready Direct RNA NASBA Urine can be used wet or lyophilized, enabling transition from liquid assay development to ambient-stable point-of-care formats without reformulating.
Have questions about a product?
Key Product Features
-
High Sensitivity: Detects RNA from both minimally processed and purified urine samples
-
Simplified workflow: One-step process requiring only the addition of primers and molecular beacons, eliminating the need for a denaturation step
-
Reduced Assay Development Time: Pre-optimized master mix for rapid deployment.
-
Point-of-Care Ready: Lyo-ready for ambient-temperature stable assays, eliminating cold-chain dependence.
Sensitivity in the Presence of Human Urine
Lyo-Ready Direct RNA NASBA Urine (MDX223) was used in a serial dilution of SARS-CoV2 RNA (1,000, 100, 50 and 10 copies respectively), in 5% pooled human urine. Error bars in the histogram represent the standard deviation across three technical replicates, these technical replicates are merged in the amplification plots. The results illustrate the high level of sensitivity and reproducibility of Lyo-Ready Direct RNA NASBA Urine with urine.
Description
The Lyo-Ready Direct RNA NASBA Urine Mix (MDX223) is a glycerol-free, lyophilization-ready master mix developed for rapid RNA detection from urine samples using NASBA. In contrast to conventional NASBA protocols, which require a pre-denaturation step at 65 °C to prepare RNA and primers, Lyo-Ready Direct RNA NASBA Urine streamlines the process into a single-pot, one-step NASBA procedure without the need for thermal denaturation. Additionally, its glycerol-free, lyo-excipient-enhanced formulation supports freeze-drying, simplifying the development of ambient-temperature stable assays that are particularly well-suited for point-of-care (POC) urine testing.
Urinary tract infections (UTIs) affect over 150 million people worldwide and are the second most common cause of infection in primary and secondary care. Most women experience at least one episode of acute uncomplicated cystitis in their lifetime. UTIs are responsible for a major part of antibiotic prescriptions, accounting for almost a quarter of antimicrobial use in the community, with antibiotic use being one of the major drivers of antimicrobial resistance.
With the stigma attached to sexually transmitted diseases (STDs), and with their rapid spread in the last few years, there is also a need for discrete, fast and accurate point-of-care (POC) tests as well.
Lyo-Ready Direct RNA NASBA Urine is purpose-built for inhibitor-rich urine samples, enabling reliable RNA amplification where conventional molecular workflows often require extensive sample preparation. It tolerates inhibitors, delivers rapid results at low temperatures, and includes lyo-excipients for ambient-temperature stable assays. These features make it ideal for near-patient testing with high sensitivity and operational simplicity.
Key Features
- High Sensitivity: Detects RNA from both minimally processed and purified urine samples
- Simplified workflow: One-step process requiring only the addition of primers and molecular beacons, eliminating the need for a denaturation step
- Reduced Assay Development Time: Pre-optimized master mix for rapid deployment.
- Point-of-Care Ready: Lyo-ready for ambient-temperature stable assays, eliminating cold-chain dependence.
Lyo-Ready Direct RNA NASBA Urine, MDX223
Single pot, one-step Nucleic Acid Sequence-Based Amplification (NASBA) for reliable isothermal amplification of RNA transcripts from crude or purified urine samples, ideal for POC testing
Available in 50 reactions (400 µL) and 250 (2 mL) reactions aliquots
Catalogs & Brochures
Catalog
FAQs: Lyo-Ready Direct RNA NASBA Urine Mix
What enzymes are used in the NASBA mix?
Three enzymes are used in the NASBA mix: reverse transcriptase, RNase H and RNA polymerase. The RT enzyme synthesizes the complementary DNA strand of a given RNA using one of the primers included in the reaction. RNase H removes the RNA template from RNA-DNA hybrid to allow binding of the second primer to cDNA, producing double-stranded DNA by RT enzyme. Afterward, the polymerase transcribes the double-stranded DNA to copy the RNA target.
What are the advantages of NASBA over traditional PCR?
NASBA is isothermal (amplification of the RNA is usually carried out at 41°C), so it does not require thermal cycling, which simplifies the equipment and reduces the risk of temperature-related errors. It is specifically designed for RNA targets, making it highly suitable for detecting RNA viruses and mRNA. NASBA amplifies RNA rapidly with high sensitivity, making it useful for applications requiring quick results.
What are the limitations of NASBA?
The requirement for multiple enzymes and specific reaction conditions can make NASBA more complex to set up compared to some other methods, to overcome these difficulties, and to make this technology more accessible, we developed the NASBA mixes, which are pre-optimized and ready-to-use The design of primers must also be highly specific to the target RNA to avoid non-specific amplification and one of the primers must include a T7 promoter sequence for RNA transcription by T7 RNA polymerase.
Can NASBA be used for DNA targets?
NASBA is primarily designed for RNA amplification. However, DNA targets can be indirectly detected if they are first transcribed into RNA using an additional transcription step.
What are the applications of NASBA?
NASBA has been used in medical diagnostics from urine, to detect RNA viruses such as Chikungunya Virus, Hepatitis C Virus, West Nile Virus, Zika Virus and Yellow Fever Virus.
Get in Touch with a Life Science Specialist
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.